When is a Medical Treatment Worth $850,000? The Value of Luxturna and Gene Therapy Treatments: A Health Policy and Bioethics Consortium
This event is free and open to the public, but space is limited and registration is required. Please note that attendees will need to show ID in order to enter the venue. Register now!
Jason I. Comander, MD, PhD, Assistant Professor of Ophthalmology; Associate Director, Inherited Retinal Disorders Service, Massachusetts Eye and Ear
Steven D. Pearson, MD, MSc, President, Institute for Clinical and Economic Review
The Health Policy and Bioethics Consortia is a monthly series that convenes two international experts from different fields or vantage points to discuss how biomedical innovation and health care delivery are affected by various ethical norms, laws, and regulations.
They are organized by the Harvard Medical School Center for Bioethics and the Program on Regulation, Therapeutics, and Law (PORTAL) at Brigham and Women's Hospital, in collaboration with the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School. Support provided by the Oswald DeN. Cammann Fund at Harvard University.